The global auto-injectors market is anticipated to grow at a significant CAGR of 15% during the forecast period. The key factors driving the market growth are the rising anaphylaxis cases across the globe as it is the most deadly food reaction and causes various deadly allergies. According to the data released by the National Center of Biotechnology Information in 2019, across the globe anaphylaxis caused in children is varied. 1- 761 per 100,00 people every year for anaphylaxis and 1 to 77 per 100 000 people per year are induced by food-induced anaphylaxis. Moreover to fight the increasing incidence of this disease various companies are focusing on developing products and fulfilling the demand of the customers.  For instance, in August 2019, Teva Pharmaceutical Industries launched its EpiPen Jr®1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the US market. The company has an exclusive License, Development, and Supply Agreement for epinephrine auto-injector products and is approved by FDA.

Impact of COVID-19 Pandemic on Global Auto-Injectors Market

COVID-19 has impacted the auto-injectors market in a positive manner as well as unfavorable impacts on the healthcare industry. Most autoinjector products are being administered at home and used in home care settings by patients across the globe. Moreover, patients who are using autoinjectors don't have to leave them and maintained social distance and receive care at home, which is advantageous when trying to maintain social distance during the COVID-19. The rising COVID-19 patient population has put a strain on the availability of medical supplies coupled with it the demand for medical supplies increased that includes, including injections, auto-injectors, pre-filled syringes, and others. Thus attributed to it manufacturers have increased their production capacity to meet the demand-increased by the patient pool. 

Segmental Outlook 

The auto-injectors are segmented on the basis of type, application, and end-user. Based on type, the market is segmented into disposable auto-injectors and reusable auto-injectors. On the basis of application, the market is sub-divided rheumatoid arthritis, multiple sclerosis, anaphylaxis, and others. Furthermore, based on end-user, the market is sub-classified into the home care settings, hospitals & clinics, and others. Among the type segment, the disposable sub-segment is holding a prominent share owing, they can be easily used and can be used on patients' convenience and preference. Moreover, due to their disposable nature, they do not cause harm and any infection can not be transferred with these injectors from one person to another. For instance, in March 2021, Jabil Healthcare collaborated with E3D for taking access to E3D's auto-injector and to develop a high-volume reusable autoinjector and connected variants. These new auto-injectors for a range of dosing volumes and patient-centric benefits and this collaboration are moving the company into the future of connected, digital devices that are more intuitive, economical, and sustainable.

Global Auto-Injectors Market Share by Application, 2021 (%)

The Rheumatoid Arthritis Segment is Dominating the Global Auto-Injectors Market

The Rheumatoid Arthritis segment is holding a prominent share in the market due to the rising incidence of Rheumatoid arthritis and the sudden increase in prevalence are factors that are contributing to the market growth. For instance, as per the report published by Healthline Media in July 2021, approximately 71 people out of 100,000 people each year are diagnosed with Rheumatoid arthritis and women are 2-3 times more affected than males by this. Moreover, 1.5 million people in America are suffering from rheumatoid arthritis. Moreover, As to the National Library of Medicine in May 2021, regarding the increasing prevalence of rheumatoid arthritis, a meta-analysis was done in which 67 studies and 742,246 RA patients and 211,592,925 were taken. In this analysis tota 0.45% in the year 1986-2014,  0.46% in 1955-2015, and between 1980-2019 460 per 100,000 population across the globe prevalence was increased with geographical location. Furthermore, rheumatoid arthritis is majorly preventable in the geriatric population and its increasing prevalence is boosting the market growth. Additionally, patients treated with auto-injectors are more comfortable using other devices for treatment such factors are propelling the market growth.

Regional Outlooks

The global auto-injectors market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East &Africa, and Latin America.  North America is estimated to be the dominating region in the global auto-injectors market owing to the well-established healthcare infrastructure and increasing patient pool with various health issues in the region.

Global Auto-Injectors Market Growth, by Region 2022-2028

The Asia Pacific Region is Fastest Growing in the Global Auto-Injectors market

The Asia Pacific is anticipated to witness the fastest growth in the market owing to the rising incidence of diabetes, rheumatoid arthritis, anaphylaxis, and others are increasing the auto-injector's demand for the treatment of diseases. Moreover, the increasing cases of food allergies in emerging countries such as India, Japan, China, and other countries are driving the market growth. Furthermore, increasing medical tourism in the region is propelling market growth. Moreover, various companies such as Johnson & Johnson Services, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., and others are contributing to the market growth by heavily investing in the development and production of the product launches in the market. For instance, in July 2021, ALK Abello signed an agreement with China Grand Pharmaceutical and Healthcare Holdings, in which they had planned to launch adrenaline auto-injector (AAI) registration and launch in China. In this new collaboration, ALK received upfront registration and it will manufacture and supply Jext autoinjectors in the Chinna market.

Market Players Outlook

The competitive landscape includes key strategies of leading players, recent developments, and key company analysis. The major players that contribute to the growth of the market include AbbVie Inc., Amgen Inc., Johnson & Johnson Services, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Ypsomed AG,  and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2022, Halozyme acquired Antares Pharma, for about $960 million, or $5.6 per share to enter into the auto-injector realm. The company's new acquisition is brought to use auto-injector technologies to add to Halozyme's Enhanze drug delivery technology. This new platform will utilize Jhonson & Jhonson multiple myeloma therapy Darzalex Faspro and Roche's Phesgo.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global auto-injectors market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.